The study also showed that the inhibition of EZH2 in pancreatic tumors induces an upregulation of p27kip1, arresting cell cycle progression and strongly sensitizing PDAC cells to gemcitabine treatment [128]. This evidence concerns the gene CDKN1B and pancreatic neoplasm.